Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

August 2016

Reminder: Co-Prescribing Naloxone Products With Opioids


As detailed in this article from the May issue of Network Matters, Harvard Pilgrim encourages providers to issue accompanying prescriptions for appropriate naloxone products to patients who are prescribed opioids and display factors that increase the risk of overdose, such as a history of substance abuse.

The newly approved narcan (naloxone hydrochloride) nasal spray is covered with no member cost share and is simple to use in the case of an emergency. Its effectiveness and ease of use present a tremendous advantage in the emergency treatment of known or suspected overdose.

The American Academy of Pain Management recently issued a statement for providers who prescribe opioids that recommends conducting comprehensive assessments of overdose risk in patients who are prescribed opioids, discussing appropriate use of opioid analgesics with them, and offering an accompanying prescription for an FDA-approved naloxone product.

In their 2016 Guideline for Prescribing Opioids for Chronic Pain, the Centers for Disease Control and Prevention also recommended issuing naloxone prescriptions when factors exist that increase the risk of overdose, such as history of overdose, history of substance use disorder, opioid doses higher than 50 MME per day, or concurrent benzodiazepine use.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Publication on Healthy Eating For Older Adults

CLINICIAN CORNER

Updated Coverage Criteria for Hepatitis C Drugs

Harvard Pilgrim Preferred Insulin Products

Prior Authorization Required for Tresiba

Reminder: Co-Prescribing Naloxone Products With Opioids

Harvard Pilgrim to Cover Hymovis With Prior Authorization

Behavioral Health Care During Transition to College

OFFICE ASSISTANT

Reminder: Use Participating Laboratory Providers

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator